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Abstract
Background Accurate preoperative staging is important
in determining the appropriate treatment of gastric cancer.
Recently, endoscopic ultrasound (EUS) has been intro-
duced as a staging modality. However, reported test char-
acteristics for EUS in gastric cancer vary. Our purpose in
this study was to identify, synthesize, and evaluate findings
from all articles on the performance of EUS in the preop-
erative staging of gastric cancer.
Methods Electronic literature searches were conducted
using Medline, Embase, and the Cochrane Central Register
of Controlled Trials from 1 January 1998 to 1 December
2009. All search titles and abstracts were independently
rated for relevance by a minimum of two reviewers. Meta-
analysis for the performance of EUS was analyzed by
calculating agreement (Kappa statistic), and pooled esti-
mates of accuracy, sensitivity, and specificity for all EUS
examinations, using histopathology as the reference stan-
dard. Subgroup analyses were also performed.
Results Twenty-two articles met our inclusion criteria
and were included in the review. EUS pooled accuracy for
T staging was 75% with a moderate Kappa (0.52). EUS
was most accurate for T3 disease, followed by T4, T1, and
T2. EUS pooled accuracy for N staging was 64%, sensi-
tivity was 74%, and specificity was 80%. There was sig-
nificant heterogeneity between the included studies.
Subgroup analyses found that annual EUS volume was not
associated with EUS T and N staging accuracy (P = 0.836,
0.99, respectively).
Conclusion EUS is a moderately accurate technique that
seems to describe advanced T stage (T3 and T4) better than
N or less advanced T stage. Stratifying by EUS annual
volume did not affect EUS performance in staging gastric
cancer.
Keywords Gastric cancer  Preoperative diagnosis 
TNM staging  EUS  Meta-analysis
Introduction
Gastric cancer has a very poor prognosis. The outcomes of
patients with gastric cancer are determined by histopatho-
logic factors, such as depth of invasion, nodal status, and
distant metastases [1]. Optimal treatment of patients with
gastric cancer depends on accurately staging the cancer,
and is most commonly accomplished through computed
tomography (CT). Recently, endoscopic ultrasound (EUS)
has been endorsed for the preoperative staging of gastric
Electronic supplementary material The online version of this
article (doi:10.1007/s10120-011-0115-4) contains supplementary
material, which is available to authorized users.
R. Cardoso  N. Coburn (&)  R. Seevaratnam  A. Mahar
Sunnybrook Research Institute,
Sunnybrook Health Sciences Centre, Toronto, Canada
e-mail: natalie.coburn@sunnybrook.ca
N. Coburn  C. Law
Division of Surgical Oncology, Sunnybrook Health Sciences
Centre and Odette Cancer Centre, Suite T2-60,
2075 Bayview Ave, Toronto, ON M4N 3M5, Canada
N. Coburn  R. Sutradhar  C. Law  J. Tinmouth
Institute for Clinical Evaluative Sciences, Toronto, Canada
L. G. Lourenco
Department of Surgery, Federal University of Sao Paulo,
Sao Paulo, Brazil
E. Yong  J. Tinmouth
Division of Gastroenterology, Department of Medicine,
Sunnybrook Health Sciences Centre, Toronto, Canada
123
Gastric Cancer (2012) 15 (Suppl 1):S19–S26
DOI 10.1007/s10120-011-0115-4
cancer by several groups, such as the National Compre-
hensive Cancer Network, the Brazilian Society of Gastro-
intestinal Endoscopy, and the Scottish Intercollegiate
Guidelines Network [2–4].
Endoscopic ultrasound
Endoscopic ultrasound (EUS) was introduced into clinical
practice in the early 1980s as a way to assess the extent of
local tumor infiltration and local lymph node status [5–7].
The main advantage of EUS is the ability to place the
transducer close to the lesion without interference of fat,
bowel gas, or bone [6]. EUS allows evaluation of the
individual layers of the gastric wall, as well as the identi-
fication of enlarged regional lymph nodes and metastasis in
the liver; thus, it may be used to stage gastric cancer
according to the TNM classification [1, 8]. In particular,
EUS is used to determine whether patients with early can-
cers are appropriate candidates for endoscopic mucosal
resection [9]. Furthermore, EUS may also be helpful in
planning the appropriate treatment strategy in patients with
advanced gastric cancer (AGC), such as determining which
patients are suitable for neoadjuvant chemotherapy or a
multivisceral resection. To date, EUS imaging can be per-
formed with echoendoscopes or with the use of ultrasound
catheters or ‘miniature probes’ which are passed through
standard endoscopes. These miniature probes can provide
ultra-high-frequency imaging (12–30 MHz), compared to
echoendoscopes (5–12 MHz). Higher frequency yields
higher resolution of the tumor at the expense of depth of
penetration, thus limiting nodal examination [1, 2]; thus, a
higher frequency probe may provide better evaluation of a
T1/T2 cancer, while a lower frequency probe may be more
accurate in predicting nodal involvement.
Unfortunately, EUS also presents some disadvantages. It
is one of the most demanding endoscopic procedures and
thus is highly operator-dependent. Extensive training and
experience in the use of the echoendoscope are required to
obtain complete and accurate images [10]. It cannot be
performed adequately when the endoscope cannot be well
positioned because of the tumor location, or when the full
extent of the tumor cannot be visualized because of high-
grade strictures [6]. Although EUS is well suited for the
evaluation of local invasion, it is of limited usefulness in the
overall assessment of more distant spread [6]. Furthermore,
EUS is an invasive technique requiring sedation and has
recognized procedure- and sedation-related complications,
including mortality [6]. Lastly, EUS adds incremental costs,
and therefore should be used only if it contributes signifi-
cantly to improved patient management and outcomes [11].
Several studies have compared the preoperative en-
dosonographic assessment of T and N stage with histopa-
thological staging of the resected specimen. However, the
results from these studies vary considerably. Therefore, the
goals of this meta-analysis were to: (1) comprehensively
identify, synthesize, and evaluate findings from articles on
the accuracy of EUS in the preoperative staging of gastric
cancer; (2) determine EUS accuracy for different T stages
(T1, T2, T3, and T4); and (3) verify EUS sensitivity and
specificity for N staging.
Methods
Data sources
Electronic literature searches were conducted using Med-
line and Embase from 1 January 1998 to 1 December 2009
according to the search algorithm presented in Appendix A.
Search terms included: [exp Stomach Cancer/or (((gastric
or stomach) adj1 cancer$) or ((gastric or stomach) adj1
carcinoma) or ((gastric or stomach) adj1 adenocarcinoma)
or ((gastric or stomach) adj1 neoplasm$)).mp.] and [exp
gastrointestinal endoscopy/or esophagogastroduodeno-
scopy/or endoscopy/or digestive tract endoscopy/or
ESOPHAGOSCOPY/or cancer staging/or exp endoscopic
therapy/or exp endoscopic surgery/or endoscopic mucosal
resection/or endoscopic echography/or ‘‘endoscopic ultra-
sound’’.mp. or endoscopic echography/] and [human and
English language] and [clinical trial/or controlled clinical
trial/or exp comparative study/or meta-analysis/or multi-
center study/or exp practice guideline/or randomized con-
trolled trial/] not [*gastrointestinal stromal tumor/] or [exp
B cell lymphoma/and ‘‘marginal zone’’.mp.] not [case
report/or review]. A separate search of the Cochrane
Central Register of Controlled Trials (1998–2009) was
performed using the search term ‘‘gastric cancer’’. No
attempt was made to locate unpublished material or contact
researchers for unpublished studies.
Study selection and review process
To be eligible, studies had to meet the following criteria:
(1) the diagnostic/staging accuracy of EUS in patients with
histologically proven gastric cancer was investigated, (2)
studies involving only patients submitted to a gastrectomy,
(3) no age or gender restrictions, (4) publication in a peer-
reviewed journal from 1 January 1998 to 1 December 2009,
and (5) publication in English. We excluded (1) reviews,
meta-analyses, systematic reviews, abstracts, editorials or
letters, case reports, and guidelines; (2) studies involving
fewer than 30 patients; (3) studies evaluating mixed can-
cers with combined data analysis; (4) studies that did not
provide sufficient information to determine at least one of
the preoperative staging performance measures (accuracy,
sensitivity, or specificity); (5) animal and ex vivo studies;
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(6) studies in which patients were presurgically treated
with radiotherapy or chemotherapy; and (7) studies that did
not use the TNM classification system.
All electronic search titles, selected abstracts, and full-
text articles were independently assessed by a minimum of
two reviewers (NC, JT, or RC). Reference lists from review
papers and relevant articles were also examined for addi-
tional studies that met our inclusion criteria. Disagreements
on study inclusion/exclusion were resolved with a con-
sensus meeting.
Data extraction
A systematic approach to data extraction was used to pro-
duce a descriptive summary of participants, interventions,
and study findings (Table 1). The first reviewer (RC) inde-
pendently extracted the data and a second reviewer (NC or
JT) reviewed the data extraction. Only data on patients who
underwent a preoperative EUS assessment and subsequent
surgery with pathologic examination were extracted. In this
review, if a selected article presented or compared EUS
performance with the performance of another procedure on
gastric cancer staging (e.g., CT, magnetic resonance imaging
[MRI]) only the results related to EUS performance were
considered for analysis. No attempt was made to contact
authors for additional information.
Quality of studies
A number of criteria and tools to assess quality of studies
have been developed [12–14]. However, there is a lack of
consensus on how to best assess the quality of non-ran-
domized clinical trials [1, 15]. Consequently, for this meta-
analysis, studies were selected based on completeness of
data and inclusion criteria only [1].
Data analysis
Descriptive characteristics were collected for each included
study. A wide range of definitions was found for the calcu-
lation of accuracy, sensitivity, and specificity. Therefore, the
following performance characteristics were re-calculated
from the original numbers provided in each included publi-
cation: accuracy, agreement (Kappa statistic), sensitivity,
and specificity. Accuracy was defined as the proportion of
tumors where staging using EUS agreed with the postoper-
ative staging using histopathology. We constructed 4 9 4
tables for T stage (corresponding to T1, T2, T3, and T4) or
5 9 5 tables when the preoperative imaging technique did
not detect the presence of a tumor (T0). Similarly, we created
2 9 2 tables for preoperative N staging (corresponding to N0
and N?). Using these tables, we calculated agreement
between EUS technique and pathology for T and N
assessment using the Kappa statistic [16]. Also, using the
tables for preoperative N staging, we calculated the sensi-
tivity and specificity of lymph node staging.
The meta-analyses were calculated using the inverse vari-
ance method; 95% confidence intervals (CIs) were calculated
for the pooled estimates of the accuracy, Kappa statistic,
sensitivity, and specificity. Non-overlapping 95% CIs were
used to determine a significant difference between groups
[16]. The following interpretation of Kappa was used:
\0 = less than chance agreement, 0.01–0.20 = slight
agreement, 0.21–0.40 = fair agreement, 0.41–0.60 = mod-
erate agreement, 0.61–0.80 = substantial agreement,
0.81–0.99 = almost perfect agreement [16].
I2 and Cochran’s Q tests were performed to assess the
heterogeneity between studies (for the Cochran Q test,
heterogeneity was present if P \ 0.05, while values of I2 to
25, 50, and 75% represented low, moderate, and high
heterogeneity, respectively). As significant heterogeneity
was identified, the EUS annual volume was investigated as
a potential cause. We calculated annual volume by dividing
the total number of cases by the number of reported years
of study. Studies were grouped by annual volume and
according to accuracy; 2 9 2 tables were constructed. For
annual volume, we stratified centers into those that per-
formed more than, and those that performed less than, 30
EUS procedures per year. For the pooled accuracy of T and
N staging, we divided centers into those with EUS accu-
racy higher than 70% and those with accuracy lower than
70%. We also aimed to explore the transducer frequency as
a source of heterogeneity by investigating the diagnostic
accuracy in different stages according to the type of
transducer frequency. We attempted to divide studies into
those that used a higher-frequency transducer ([12 MHz)
and those that used a lower-frequency transducer
(B12 MHz) to compare the EUS accuracy (EUS accuracy
higher than 70% and lower than 70%) for all T staging. Six
studies used a combination of both low- and high-fre-
quency transducers (as shown in Table 1). Unfortunately,
these studies did not clearly report when the low- or high-
frequency transducers were used; as a result they were
excluded. No studies exclusively used high-frequency
transducers. Consequently, it was possible to identify only
one group of studies (B12 MHz). Therefore, it was not
feasible to create comparison groups.
Statistical analyses were performed using the R version
2.10.1 statistical package (The R Foundation for Statistical
Computing, ISBN 3-900051-07-0, http://cran.r-project.org/).
Results
A total of 7117 titles were identified from the electronic
and hand searches for preliminary review. After removal of
EUS preoperative TNM staging S21
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duplicates and screening for relevant titles and abstracts,
122 articles were submitted for a full review. A total of 22
were included [7, 17–37] (Fig. 1); the characteristics are
presented in Table 1. A total of 2445 patients were staged
preoperatively by EUS; the majority were from studies
from Asia (1892 patients), followed by Europe (337
patients), and North America (216 patients). The majority
of participants presented with T3 disease (n = 873), fol-
lowed by T2 disease (n = 734), T1 disease (n = 584), and
T4 disease (n = 254).
T stage
The diagnostic accuracy of EUS for overall T staging
varied between 56.9 and 87.7% and the pooled accuracy
was 75% (95% CI: 71–80%) with a moderate pooled
Kappa (0.52; 95% CI: 0.38–0.67). For T1, individual study
accuracy ranged from 14 to 100% and the pooled accuracy
was 77% (95% CI: 70–84%) (Fig. 2). T2 staging accuracy
ranged from 24 to 90% and the pooled accuracy was 65%
(95% CI: 57–73%) (Fig. 3). Accuracy ranged from 50 to
100% for T3 staging and the pooled accuracy was 85%
(95% CI: 82–88%) (Fig. 4). EUS accuracy for T4 staging
ranged from 25 to 100% and the pooled accuracy was 79%
(95% CI: 68–90%) (Fig. 5). The 95% CIs for the pooled
accuracies overlap in forest plots for all T stages, indicating
that they are not statistically different from each other. The
calculated I2 value for all pooled accuracy estimates was
89.5% (95% CI: 85–92%). The Cochran Q test confirmed
that the included studies were heterogeneous (P \ 0.0001).
Table 1 Characteristics of included studies
Author Country Study type N Instrumentation used Frequency of probe
Ahn [17] Korea P 71 Radial array 5 and 12 MHz
Akahoshi [18] Japan P 78 (1) Ultrathin mechanical radial scanning probe with a 2.6-mm
probe, (2) electronic endoscopes EVG-CT (Fujinon) or GIF-Q200
(Olympus)
(1) 15 MHz, (2) NR
Ang [7] Singapore P 57 Radial EES—GF UM20 (Olympus) 7.5–12 MHz
Barbour [19] Japan R 209 GF-UM3 (Olympus), GF-UM130 (Olympus) or MH-908 radial
scanning EES (Olympus)
7.5 and 12 MHz
Bentren [20] USA R 225 Transducer from the Olympus Corporationa 7.5–12 MHz
Bhandari [21] Korea P 63 UM-2R/3R (Olympus) and GF-UMQ 200 radial scanning EES
(Olympus)
7.5–20 MHz
Chen [22] Taiwan R 57 45 oblique viewing EES—GF-UM 20 (Olympus) 7.5–12 MHz
Ganpathi [23] Singapore R 102 Radial EES—GF-UM20 (Olympus) 7.5 or 12 MHz
Habermman [24] Germany P 51 Radial EES—GF UM2, GF-UM3 (Olympus) 7.5 or 12 MHz
Hizawa [25] Japan P 226 GF-UM conventional radial-sector transducers, GF-UM20
miniature probe system, UM-2R and UM-3R (all Olympus)
12–20 MHz
Javaid [26] India NC 112 GF-UM3 EES (Olympus) 7.5 MHz
Kida [27] Japan NC 1551 (1) CEUS, (2) NCEUS, (3) UP, (4) 3D, XEU-IP automatic
mechanical spiral scanning
12 and 20 MHz
Kim [28] Korea R 206 (1) GF-240 (Olympus), (2) GFUM-2000 (Olympus), (3) Miniprobe 5–20 MHz
Lee [29] China P 241 (1) GF-UM20 EES, (2) GF-UM240 EES 7.5 and 12 MHz
Polkowski [30] Poland P 88 GF-UM20 radial EES (Olympus) 7.5 and 12 MHz
Potrc [31] Slovenia P 82 EUM-20 radial technology ultrasound probe (Olympus) 7.5 and 12 MHz
Shimoyama [32] Japan R 45 Endoscope with linear probe at the distal end 7.5 MHz
Tan [33] China NC 63 (1) GF-240 electronic gastroscope (Olympus), (2) GF-UMQ 240
electro-ultrasonic gastroscope, 360 circular scan (Olympus)
7.5–20 MHz
Tsendsuren [34] China NC 41 EG-3630U (Pentax), EUB-525 (Hitachi). EES with real-time
ultrasound imaging linear scanning transducers and Doppler
5.0 and 7.5 MHz
Wang [35] China P 119 GF-UM3 radial sector scan transducer (Olympus) 7.5 or 12 MHz
Willis [36] Germany P 116 GIF-UM20 radial scanning (Olympus) 7.5–12 MHz
Xi [37] China NC 35 Fujinon SP-701 radial scanning probes 7.5, 12 and 20 MHz
P prospective, R retrospective, NC not clear/not sufficient details to determine, NR not reported, N number of patients, CEUS conventional
endoscopic ultrasound (EUS), NCEUS new conventional EUS, UP ultrasound probe, 3D three-dimensional, EES echoendoscope
a More details not given
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N stage
EUS diagnostic accuracy for N staging ranged from 30 to
90%; sensitivity ranged from 16.6 to 96.8%; and specificity
from 57.1 to 100%. The pooled accuracy for N staging was
64% (95% CI: 43–84%); the pooled sensitivity was 74%
(95% CI: 66–81%); and the pooled specificity was 80%
(95% CI: 74–87%) (Figs. 6, 7). The calculated I2 values for
pooled sensitivity and specificity were I2 = 89.9% (85.8%;
92.9%) and I2 = 85.6% (78.8%; 90.2%), respectively. The
Cochran Q test revealed that the studies included were
heterogeneous (P \ 0.0001).
Effect of annual volume
Subgroup analyses did not demonstrate an association
between EUS performance in T and N staging and EUS
annual volume (P = 0.836, 0.99, respectively).
Articles excluded based on title and abstract = 6907 
Articles excluded = 100 
• Topic (not diagnostic accuracy, ex vivo) = 55 
• < 30 patients = 11 
• Guideline/Review = 13 
• Mixed Cancers/ combined analysis = 13 
• Pathology was not the reference standard = 2 
• Staging classification (not TNM) = 6 
Full articles retrieved for more detailed evaluation =122 
Potential relevant articles identified and screened for retrieval = 7117 
Articles included in this systematic review = 22 
Fig. 1 Article selection flow
Fig. 2 EUS accuracy for T1 staging. N Number of patients, Acc
accuracy, SE standarderror, CI confidence interval, CEUS conven-
tional EUS, NCEUS new conventional EUS, UP ultrasound probe, 3D
three-dimensional
Fig. 3 EUS accuracy for T2 staging
Fig. 4 EUS accuracy for T3 staging
EUS preoperative TNM staging S23
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EUS examination
Combinations of different transducer frequencies were
used in the majority of the studies. Fifteen studies [7, 17,
19, 20, 22–24, 26, 29–32, 34–36] used combinations of
frequencies of B12 MHz and six studies [18, 25, 27, 28,
33, 37] used combinations of frequencies ranging from 5 to
20 MHz. It was not feasible to construct a 2 9 2 table to
investigate transducer frequencies as source of heteroge-
neity. However, based on the data from 13 studies
(B12 MHz) it was possible to confirm that EUS staging
accuracy varied vastly in the studies using low-frequency
transducers. The accuracy of T1 staging varied from 40 to
100%, T2 staging from 0 to 90%, T3 staging from 54 to
100%, and T4 staging from 0 to 100%.
Discussion
Accurate staging influences management decisions and
predicts prognosis for gastric cancer patients. It is utilized
to select patients for endoscopic or laparoscopic treatment,
for the selection of those who may benefit from less
invasive diagnostic procedures [38], and for the selection
of those who may benefit from multimodal treatment [39,
40]. However, it is operator-dependent, adds incremental
costs, and has a risk of complications, including mortality.
In the present meta-analysis of 22 studies, the pooled
accuracy of EUS for tumor invasion (T stage) was mod-
erate; however, it tended to be higher for advanced disease
when compared to early disease. EUS tended to perform
slightly worse for nodal staging, with moderate accuracy,
sensitivity, and specificity. There was significant variability
across studies resulting in statistical heterogeneity which
was not explained by the annual volume of EUS proce-
dures performed at an institution.
There are few other published systematic reviews and
meta-analyses assessing EUS performance for staging
gastric cancer. An early systematic review by Kelly et al.
[5] evaluated 27 articles, published between 1981 and
1996, of which 13 evaluated gastric cancer, and found that
EUS performed better for staging gastric carcinoma com-
pared to carcinomas of the esophagus. As with the study by
Kelly et al., we found that EUS performed better when
staging tumor invasion than when staging nodal status. In
addition, we found that EUS tended to be more accurate for
the diagnosis of more advanced T stages (T3 and T4 dis-
ease). Our findings are consistent with a meta-analysis by
Puli et al. [1], which evaluated 22 studies (1986–2006), and
also described better EUS accuracy in higher T-stage
disease.
In some of the other meta-analyses [6, 41], EUS staging
performance for T and N stage was compared with that of
Fig. 5 EUS accuracy for T4 staging
Fig. 6 EUS sensitivity for N staging. Sens sensitivity
Fig. 7 EUS specificity for N staging. Spec specificity
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other imaging modalities such as abdominal ultrasound
(AUS), conventional MRI, and CT. While these reviews
suggest that no modality consistently achieves both high
sensitivity and high specificity in staging gastric cancer,
our study did not compare EUS to other imaging modali-
ties. Our group has performed a separate meta-analysis
of radiologic imaging in the preoperative management of
gastric cancer, finding an overall accuracy for T stage of
68, 72, and 83% and an overall accuracy for N stage of 68,
66, and 53% for AUS, CT, and MRI, respectively [42]. All
meta-analyses of EUS in gastric cancer published to date
have identified significant heterogeneity in the included
studies. In our study and that reported by Kwee and Kwee
[43] subgroup analyses were performed to try to identify
the sources of heterogeneity. Kwee and Kwee [43] inclu-
ded 18 studies from 1988 to 2007 in their study and found
that heterogeneity was eliminated if studies were restricted
to those evaluating patients with early gastric cancer and
those that used transducers with frequencies less than
15 MHz. Our review showed that EUS performance for T
staging varied between studies using low-frequency trans-
ducers, but a comparison of accuracy for the high-fre-
quency probes versus the low-frequency probes was not
possible, as no studies exclusively used high-frequency
probes. Kwee and Kwee [43] also examined the total
number of patients in each study and the country of origin
of the study, both of which factors might be reflective of
operator experience, but they found that neither of these
factors explained the heterogeneity. Similarly, we thought
that operator experience, as measured by annual EUS
volume, might explain the heterogeneity. However, we
found no association between annual EUS volume and
accuracy. Therefore, this factor cannot explain the
heterogeneity.
There were a few limitations to our meta-analysis. The
majority of included patients were staged preoperatively by
EUS in Asia. Consequently, the reported results may not be
generalizable to other, lower-volume regions. Also, the
way in which individual studies reported their results
affected their inclusion in the meta-analysis. For example,
some studies reported results for T staging as T1/T2 and
T3/T4, which precluded data extraction for T stage,
although data on N staging (N0 vs. N?) could be extracted
and analyzed. Lastly, our meta-analysis, like the others that
have been previously published, demonstrated significant
heterogeneity, with no clear explanation for this. As a
result, caution must be used in interpreting the findings.
Conclusion
Our review found EUS to have only moderate agreement
and accuracy for both T and N staging. EUS may be most
useful for staging cancers with greater tumor involvement
(T3 and T4). The significant heterogeneity of the included
studies should be taken into consideration when interpret-
ing our findings. The decision to use EUS, which has only
moderate accuracy in the staging of gastric cancer, must be
balanced against the predicted change in management, as
other less invasive staging methods exist.
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